In-vitro Diagnostics Market Size & Share 2025 - 2034

In-vitro Diagnostics Market Size

The global in-vitro diagnostics market size was estimated at USD 105.7 billion in 2024. The market is expected to grow from USD 108.6 billion in 2025 to USD 155.4 billion by 2034 at a CAGR of 4.1% during the forecast period. In-vitro diagnostics (IVD) refer to medical devices, reagents, and systems which are used for the examination of specimens such as blood, urine, tissues, and other bodily fluids outside the body, to gain the information for the diagnosis, monitoring, and treatment of diseases and other health conditions.

The global in-vitro diagnostics market is experiencing significant growth, driven by the increasing prevalence of infectious diseases such as COVID-19, HIV/AIDS, tuberculosis, hepatitis, and malaria pose significant public health challenges, propelling the demand for the in-vitro diagnostic (IVD) technologies. For instance, according to the World Health Organization (WHO), HIV continues to be a significant global public health challenge, with an estimated 42.3 million lives lost to date. Transmission persists worldwide across all countries.
 

By the end of 2023, approximately 39.9 million people were living with HIV, with 65% residing in the WHO African Region. In the same year, an estimated 630,000 individuals succumbed to HIV-related causes, while 1.3 million people newly acquired the infection. Thus, these statistics highlight the vital role of IVD technologies in reducing infectious and chronic diseases and supporting global healthcare efforts.
 

Furthermore, the growing adoption and rising demand for personalized medicine, escalates the in-vitro diagnostics (IVD) market by allowing tailored treatments through advanced tools such as molecular diagnostics, which is estimated to reach USD 36 billion by 2032, and genomics. For instance, an article in the Proceedings of the National Academy of Sciences highlighted the adoption of immunotherapy, signaling a move toward precision and personalized cancer treatment. The study highlighted using individual patient characteristics to tailor optimal care and assess disease susceptibility, fueling the market growth.
 

In-vitro Diagnostics Market Trends

• The rising adoption of point-of-care testing (POCT) is transforming healthcare delivery in developing countries by bringing diagnostic capabilities closer to patients, specifically in remote and resource-limited areas. POCT focuses on challenges such as inadequate infrastructure, limited medical access, and growing infectious disease burdens by enabling timely diagnosis and treatment, improving patient management.
   
• For instance, 28% of Australia’s population resides in rural regions, while 86% of medical consultations in India involve rural residents, many traveling over 100 kilometers for care. POCT improves disease management in such areas, which leads to better health outcomes.
   
• Furthermore, technological advancements in POCT have led to the development of portable, easy-to-use POCT devices that provides high accuracy and sensitivity. For instance, Abbott's i-STAT System integrates POCT with electronic health records (EHRs), allowing healthcare providers to make informed clinical decisions promptly.
   
• Similarly, Absology Co., Ltd. launched its latest point-of-care testing (POCT) innovations at MEDICA 2023, which includes the ABSOL automated fluorescent immunoassay (FIA) analyzer and ABSOL HS. The ABSOL HS is an advanced POCT device that uses PIFA technology to enhance fluorescence for accurate disease detection in both humans and animals.
   
• Thus, these advancements improve healthcare by enabling faster and more effective diagnosis and treatment. Innovations such as miniaturization, automation, and connectivity have made decentralized testing easier, affordable, and adaptable, which helps in driving the growth in IVD market.
   

In-vitro Diagnostics Market Analysis

Based on product, the market is divided into reagents and kits, and instruments. The global market was estimated at USD 103.4 billion in 2023. The reagents and kits segment held revenue of USD 71.3 billion in 2024 and the segment is poised for significant growth at a CAGR of 4.4% during the forecast period.
 

• This growth is stimulated by rising demand for accurate diagnostic solutions, spurred by the need for early disease detection and personalized treatments.
   
• The reagents and kits segment includes a wide range of products that are essential for conducting diagnostic tests, including biochemical reagents, antibodies, probes, primers, and assay kits. Thus, these components are integral to various diagnostic techniques, such as immunoassay, molecular diagnostics, and clinical chemistry, which helps in the detection and quantification of biomarkers associated with diseases or health conditions.
   
• Further, they ensure precise and consistent test results, which reduces variability and minimizing the risk of diagnostic errors. Their standardized formulation supports in maintaining high sensitivity and specificity, which is important for detecting diseases at an early stage.
   
• For instance, Roche’s cobas SARS-CoV-2 & Influenza A/B Test provides highly accurate detection of respiratory viruses, confirming reliable diagnosis and treatment.
   
• Further, pre-packaged kits makes diagnostic procedures easier by providing ready-to-use components, helps in minimizing the complexity of sample preparation. This allows healthcare providers to perform tests accurately, making diagnostics more accessible across different healthcare settings.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on test type, the in-vitro diagnostics market is bifurcated into clinical chemistry, immunoassay/immunochemistry, molecular diagnostics, hematology, urinalysis, and other test types. The molecular diagnostics segment accounted for a 25.5% market share in 2024 and is projected for significant growth to reach USD 40.8 billion by 2034.
 

• Growing technological advancements for diagnosis is one of the major factors that will escalate the business growth due to its accuracy and portability. This has helped in the detection of various diseases.
   
• For instance, in April 2020, Roche Diagnostics’ introduced Cobas 6800/8800 system which is a fully automated assay that can simultaneously detect HPV18, HPV16, and other 12 pooled HR-HPV genotypes. Such advances are anticipated to drive the growth of market.
   
• Further, molecular diagnostics provide results faster than traditional culture-based tests, frequently within hours or minutes. For instance, the Cepheid GeneXpert System provides rapid PCR-based results for tuberculosis and sexually transmitted infections (STIs), significantly reducing diagnosis time.
   
• Further, rising awareness regarding to early disease diagnosis and its prevention has stimulated the demand for molecular diagnostics for various diseases such as detection of cancer and infectious disease at early stage. It has become integral part of disease management and therapy.
   

Based on application, the in-vitro diagnostics market is bifurcated into oncology, infectious diseases, diabetes, cardiology, nephrology, autoimmune diseases, drug testing/pharmacogenomics, and other application. The infectious diseases segment dominated the global market accounting for USD 31.2 billion in 2024.
 

• Infectious diseases are a crucial segment of the in-vitro diagnostics (IVD) market due to their widespread prevalence, public health impact, and the critical need for accurate, timely diagnosis.
   
• For instance, according to the data from UNAIDS states that in 2023, about 39.9 million people globally suffered from HIV and 1.3 million people became newly infected with HIV. Further, 6,30,000 individuals died from AIDS-related illnesses, globally.  
   
• In addition, advanced diagnostic techniques allow for precise identification of infectious diseases, which ensures that infections are accurately diagnosed. This leads to targeted treatment, minimizing the risk of misdiagnosis and inappropriate therapies. For example, Abbott’s ID NOW COVID-19 2.0 detects SARS-CoV-2 in 6-12 minutes with the option to add on an ID NOW Influenza A & B 2 test without collecting another sample, delivering rapid results by using isothermal technology to provide molecular results faster than PCR.
   
• Covering a wide range of pathogens including viruses such as HIV, hepatitis, COVID-19, bacteria, fungi, parasites, and emerging infectious agents these diagnostics are an essential tools for effective disease management and public health intervention.
   
• For instance, according the study published in National Institute of Health, Xpert MTB/RIF substantially increases TB detection among cultureconfirmed cases. Xpert MTB/RIF has higher sensitivity for TB detection in smearpositive than smearnegative patients, helping to control emerging infections. These advantages are boosting the market growth.
   

Based on end use, the in-vitro diagnostics market is bifurcated into hospitals, diagnostic laboratories, academic and research institutes, and other end users. The diagnostic laboratories segment accounted for a 44% market share in 2024.
 

• Diagnostic laboratories offer a wide range of diagnostic tests and procedures, catering to the rising demand for diagnostic services across various medical specialties.
   
• Additionally, they are equipped with state-of-the-art technology and staffed by highly skilled professionals. Diagnostic laboratories offers accurate and efficient diagnostic testing, which includes laboratory tests, genetic testing, and molecular diagnostics.
   
• These laboratories also handle a high volume of infectious disease cases, efficiently processing samples and performing large-scale IVD procedures, thereby steering market growth.
   
• Further, diagnostic laboratories often collaborate with healthcare providers, hospitals, and medical specialists to deliver integrated care and support multidisciplinary treatments.
   

The North America in-vitro diagnostics market is accounted for USD 45.1 billion revenue in 2024 forecasted to reach USD 59.9 billion by 2034. The U.S. dominated the North America market with the largest revenue of USD 40.3 billion in 2023.
 

• This growth is largely attributed to the increasing prevalence of infectious diseases in the U.S.
   
• For instance, according to the Centers for Disease Control and Prevention (CDC), in 2019, the reported number of new cases for various infectious diseases in the U.S. was as follows: 8,916 cases of tuberculosis, 58,371 cases of salmonella, 34,945 cases of Lyme disease, and 371 cases of meningococcal disease.
   
• Additionally, despite a stringent regulatory environment, there is strong support for the approval and commercialization of innovative healthcare solutions such as IVD kits, instruments.
   
• Moreover, the technological advancements and adoption of the advanced IVD kits, instruments, across the country are further boosting the growth of the market in the country.
   

Europe: The in-vitro diagnostics market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The country’s well established healthcare system and the rising demand for accurate and efficient diagnostic solutions are the key factors stimulating the growth of the market in the country.
   
• Moreover, the growing aging population base and an increasing awareness early disease detection are further solidifying the growth of market in the country.
   
• For instance, as per the data from Office for National Statistics, the elderly population of the UK is expected to rise significantly. In 2020, an estimated 2.5% of the total population comprised of people aged 85 and over, by 2040 the figure is projected to reach 4.3% of the total population.
   
• Thus, this demographic shift stimulates the need for high quality in-vitro diagnostics kits, specifically for infectious diseases diagnosis, as aging individuals are more susceptible to infections, thereby fostering the market growth in the region.
   

Asia pacific: Japan in-vitro diagnostics market is anticipated to witness lucrative growth between 2025 - 2034.
 

• The country has one of fastest aging population which necessities frequent infectious disease screening and monitoring. In-vitro diagnostics provides an effective and convenient option for diagnosing infections, impelling their adoption in the country.
   
• For example, in 2023 projections from the World Economic Forum revealed that 1 in 10 people in Japan are aged 80 years and above which is about one-third of the population.
   
• Thus, this demographic shift has created awareness among the healthcare providers and policy makers for the need of effective strategies to address age related susceptibility to the infections, thereby escalating the market growth.
   

Middle East and Africa: The in-vitro diagnostics market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia’s advance healthcare infrastructure and rising investment in advanced healthcare technologies create opening for the development and adoption of advanced in-vitro diagnostics kits, instruments tailored to the country’s patient specific needs.
   
• Further, the rising awareness regarding the importance of early and accurate infectious diseases diagnosis across various age group of individuals in the country, further propelling the market growth.
   

In-vitro Diagnostics Market Share

The top 4 players of the market account for approximately 55% of the market share which includes companies such as Abbott Laboratories, BIOMÉRIEUX, F. Hoffmann-La Roche, and Siemens Healthineers among others. These companies maintain their dominance in the market through innovative product launches, extensive distribution networks and strong regulatory approval.
 

Moreover, strategic partnerships with research institutes, and government agencies play a primary role in advancing the development of new in-vitro diagnostics kits and getting the necessary permits. The development of public awareness about infectious diseases and its health impact through the social media platform, will encourage more individuals to seek the early diagnosis and treatment, enabling market players to strengthen their position in this growing sector.
 

In-vitro Diagnostics Market Companies

Some of the eminent market participants operating in the in-vitro diagnostics industry include:

• Abbott Laboratories
• ACON Laboratories
• Agilent Technologies
• Becton, Dickinson and Company
• Biomerieux
• Bio-Rad Laboratories
• Dragerwerk
• F. Hoffmann-La Roche
• Danaher Corporation
• Medtronic
• Meridian Bioscience
• Nova Biomedical
• PerkinElmer
• Siemens Healthineers
• Sysmex Corporation
   
• F. Hoffmann-La Roche has robust geographical presence which enables it to enhance its market reach. F. Hoffmann-La Roche has presence over 100 countries and with the support of a large network of distributors, thus involving a strong distribution network.
   
• Abbott Laboratories has strong product portfolio leading to larger adoption and significant market expansion. Abbott provides a products pertaining to point of care coagulation testing products such Abbott Panbio COVID-19 Antigen Rapid Test, among others.
   
• Danaher Corporation has strong global workforce of approximately 63,000 employees, which enables the company to drive innovation, and deliver high-quality solutions.
   

In-vitro Diagnostics Industry News:

• In February 2024, BD, announced a strategic partnership with Camtech Health, a digital health company focused on at-home health testing, to advance cervical cancer screening by offering the first-ever option for women in Singapore to self-collect a sample in the privacy of their own home. This strategy increased the geographical reach of the company in the in-vitro diagnostics sector.
   
• In December 2023, Danaher Corporation announced the acquisition of Abcam plc. The acquisition of Abcam for USD 24 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006. This acquisition accelerated the in-vitro molecular diagnostic array of the company, thereby increased the sales.
   

The in-vitro diagnostics market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Reagents and kits
• Instruments

Market, By Test Type

• Clinical chemistry
• Immunoassay/immunochemistry
• Molecular diagnostics
• Hematology
• Urinalysis
• Other test types

Market, By Application

• Oncology
• Infectious diseases
• Diabetes
• Cardiology
• Nephrology
• Autoimmune diseases
• Drug testing/pharmacogenomics
• Other applications

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Academic and research institutes
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy 
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE